Walter Berger

20.6k total citations · 4 hit papers
382 papers, 15.4k citations indexed

About

Walter Berger is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Walter Berger has authored 382 papers receiving a total of 15.4k indexed citations (citations by other indexed papers that have themselves been cited), including 178 papers in Molecular Biology, 150 papers in Oncology and 52 papers in Organic Chemistry. Recurrent topics in Walter Berger's work include Metal complexes synthesis and properties (62 papers), Drug Transport and Resistance Mechanisms (42 papers) and Fibroblast Growth Factor Research (32 papers). Walter Berger is often cited by papers focused on Metal complexes synthesis and properties (62 papers), Drug Transport and Resistance Mechanisms (42 papers) and Fibroblast Growth Factor Research (32 papers). Walter Berger collaborates with scholars based in Austria, Germany and Hungary. Walter Berger's co-authors include Bernhard K. Keppler, Petra Heffeter, M. Micksche, Michael A. Jakupec, Christian R. Kowol, Leonilla Elbling, Christian G. Hartinger, Christine Pirker, Michael Grusch and Ute Jungwirth and has published in prestigious journals such as Chemical Reviews, Proceedings of the National Academy of Sciences and Journal of the American Chemical Society.

In The Last Decade

Walter Berger

364 papers receiving 15.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

KP1019, A New Redox‐Active Anticancer Agent – Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients

2008 732 citations Michael A. Jakupec, Walter Berger et al. profile →
NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application

2014 583 citations Petra Heffeter, Christian R. Kowol et al. Chemical Science profile →
Anticancer Activity of Metal Complexes: Involvement of Redox Processes

2011 439 citations Ute Jungwirth, Christian R. Kowol et al. profile →
Structure–activity relationships for ruthenium and osmium anticancer agents – towards clinical development

2017 368 citations Samuel M. Meier, Christopher Gerner et al. profile →

Peers

Countries citing papers authored by Walter Berger

Since Specialization

Citations

This map shows the geographic impact of Walter Berger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Walter Berger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Walter Berger more than expected).

Fields of papers citing papers by Walter Berger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Walter Berger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Walter Berger. The network helps show where Walter Berger may publish in the future.

Co-authorship network of co-authors of Walter Berger

This figure shows the co-authorship network connecting the top 25 collaborators of Walter Berger. A scholar is included among the top collaborators of Walter Berger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Walter Berger. Walter Berger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Selectivity for TP53 signalling drives the mode of action of a highly potent N , O , O -tridentate naphthoquinone-based organo-ruthenium anticancer drug candidate 2025 ·Chemical Science ·(unknown), (unknown), (unknown), Dina Baier, Michaela Hejl, (unknown), (unknown), (unknown), Thomas Mohr, Anton A. Legin, Michael A. Jakupec, Andrea Bileck, Christopher Gerner, Gunda Koellensperger, Petra Heffeter, Walter Berger, Bernhard K. Keppler, Wolfgang Kandioller, Samuel M. Meier	0
2	Mesothelioma-associated fibroblasts enhance proliferation and migration of pleural mesothelioma cells via c-Met/PI3K and WNT signaling but do not protect against cisplatin 2023 ·Journal of Experimental & Clinical Cancer Research ·(unknown), (unknown), Astrid Slany, Christine Pirker, Johanna C. Mader, Thomas Mohr, Karin Schelch, Katharina Sinn, (unknown), Mir Alireza Hoda, Balázs Döme, Helmut Dolznig, Georg Krupitza, Leonhard Müllauer, Christopher Gerner, Walter Berger, Michael Grusch	13
3	Combination of Drug Delivery Properties of PAMAM Dendrimers and Cytotoxicity of Platinum(IV) Complexes—A More Selective Anticancer Treatment? 2023 ·Pharmaceutics ·(unknown), Michaela Hejl, (unknown), Michael A. Jakupec, Walter Berger, M. Galanski, Bernhard K. Keppler	4
4	Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features 2020 ·Cancer Research ·Miriam Marqués, Robin Tranchant, (unknown), (unknown), Luis C. Fernández, Enrique Carrillo de Santa Pau, Natalia del Pozo, Jaime Martínez de Villarreal, Clément Meiller, Yves Allory, Yuna Blum, Christine Pirker, Balázs Hegedűs, Simon T. Barry, Amancio Carnero, Walter Berger, Didier Jean, Francisco X. Real	21
5	Ruthenium–arene complexes bearing naphthyl-substituted 1,3-dioxoindan-2-carboxamides ligands for G-quadruplex DNA recognition 2019 ·Dalton Transactions ·(unknown), (unknown), (unknown), Silvia Alonso‐de Castro, Dina Baier, Alexander Roller, Wolfgang Kandioller, Bernhard K. Keppler, Walter Berger, Luca Salassa, Alessio Terenzi	26
6	Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth In Vivo 2018 ·Clinical Cancer Research ·Viktória László, (unknown), Ildikó Kovács, (unknown), Mir Alireza Hoda, Thomas Klikovits, (unknown), András Czirók, Tamás Garay, (unknown), Thomas H. Helbich, (unknown), József Tóvári, Walter Klepetko, Christine Pirker, Michael Grusch, Walter Berger, Frank Hilberg, Balázs Hegedűs, Balázs Döme	25
7	Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro 2016 ·Molecular Cancer Therapeutics ·Mir Alireza Hoda, Christine Pirker, (unknown), Karin Schelch, Petra Heffeter, Kushtrim Kryeziu, Sushilla van Schoonhoven, Thomas Klikovits, Viktória László, Anita Rózsás, (unknown), Walter Klepetko, Balázs Döme, Michael Grusch, Balázs Hegedűs, Walter Berger	17
8	Vemurafenib Resistance Signature by Proteome Analysis Offers New Strategies and Rational Therapeutic Concepts 2015 ·Molecular Cancer Therapeutics ·Verena Paulitschke, Walter Berger, (unknown), (unknown), Bernhard Knapp, (unknown), Dagmar Födinger, Walter Jäger, Thomas Szekeres, Anastasia Meshcheryakova, Andrea Bileck, Christine Pirker, Hubert Pehamberger, Christopher Gerner, Rainer Kunstfeld	25
9	Calpain-Mediated Integrin Deregulation as a Novel Mode of Action for the Anticancer Gallium Compound KP46 2014 ·Molecular Cancer Therapeutics ·Ute Jungwirth, Johannes Gojo, (unknown), Gernot Walko, Martin Holcmann, (unknown), Karin Nowikovsky, (unknown), Sushilla van Schoonhoven, Christian R. Kowol, Rosa Lemmens‐Gruber, Petra Heffeter, Bernhard K. Keppler, Walter Berger	19
10	Spatio‐temporally precise activation of engineered receptor tyrosine kinases by light 2014 ·The EMBO Journal ·Michael Grusch, Karin Schelch, (unknown), Eva Reichhart, (unknown), Walter Berger, Álvaro Inglés‐Prieto, Harald Janovjak	199
11	Novel Inhibitors of Cyclin-Dependent Kinases Combat Hepatocellular Carcinoma without Inducing Chemoresistance 2013 ·Molecular Cancer Therapeutics ·(unknown), Markus Grubinger, Eva Řezníčková, Thomas S. Weiß, Hans Rotheneder, Walter Miklos, Walter Berger, Radek Jorda, Marek Zatloukal, Tomáš Gucký, Miroslav Strnad, Vladimı́r Kryštof, Wolfgang Mikulits	27
12	Synergistic Anticancer Activity of Arsenic Trioxide with Erlotinib Is Based on Inhibition of EGFR-Mediated DNA Double-Strand Break Repair 2013 ·Molecular Cancer Therapeutics ·Kushtrim Kryeziu, Ute Jungwirth, Mir Alireza Hoda, Franziska Ferk, Siegfried Knasmüller, (unknown), Christian R. Kowol, Walter Berger, Petra Heffeter	44
13	Differential Effects of Polymorphic Alleles of FGF Receptor 4 on Colon Cancer Growth and Metastasis 2012 ·Cancer Research ·Christine Heinzle, Andrea Gsur, (unknown), (unknown), Christine Gauglhofer, Stefan Stättner, J. Karner, M. Klimpfinger, Friedrich Wrba, (unknown), Balázs Hegedűs, Andreas Baierl, Bettina Grasl‐Kraupp, Klaus Holzmann, Michael Grusch, Walter Berger, Brigitte Marian	41
14	The major vault protein mediates resistance to epidermal growth factor receptor inhibition in human hepatoma cells 2012 ·Cancer Letters ·Annemarie Losert, Daniela Lötsch, Andreas Lackner, Herwig Koppensteiner, (unknown), Elisabeth Steiner, Klaus Holzmann, Thomas W. Grunt, Katharina Schmid, Brigitte Marian, Bettina Grasl‐Kraupp, Rolf Schulte‐Hermann, Georg Krupitza, Walter Berger, Michael Grusch	29
15	A Human Model of Epithelial to Mesenchymal Transition to Monitor Drug Efficacy in Hepatocellular Carcinoma Progression 2011 ·Molecular Cancer Therapeutics ·Franziska van Zijl, Sabine Mall, Georg Machat, Christine Pirker, Robert Zeillinger, Andreas Weinhaeusel, Martin Bilban, Walter Berger, Wolfgang Mikulits	57
16	Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells 2009 ·Molecular Cancer Therapeutics ·Beata Herberger, Walter Berger, Harald Puhalla, Katharina Schmid, Sabine Novak, Anita Brandstetter, Christine Pirker, Thomas Gruenberger, Martin Filipits	26
17	Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition 2008 ·Molecular Cancer Therapeutics ·Hendrik Fischer, Ninon Taylor, (unknown), Michael Grusch, (unknown), Klaus Holzmann, Ulrike Setinek, Leonilla Elbling, (unknown), Bettina Grasl‐Kraupp, Christine Gauglhofer, Brigitte Marian, M. Micksche, Walter Berger	86
18	Expression of the major vault protein LRP in human non‐small‐cell lung cancer cells: Activation by short‐term exposure to antineoplastic drugs 2000 ·International Journal of Cancer ·Walter Berger, Leonilla Elbling, M. Micksche	8
19	Expression of the major vault protein LRP in human non-small-cell lung cancer cells: Activation by short-term exposure to antineoplastic drugs 2000 ·International Journal of Cancer ·Walter Berger, Leonilla Elbling, M. Micksche	93
20	A novel bioassay for P-glycoprotein functionality using cytochalasin D 1998 ·Cytometry ·Leonilla Elbling, Walter Berger, (unknown), Dieter Printz, G. Fritsch, M. Micksche	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact